UPDATE: Luminex Gains FDA Clearance for Gastro Test; Expects Clearance for Newborn Test in H2 | GenomeWeb

This article has been updated from a version posted Jan. 10 to reflect the fact that Luminex has gained clearance for its gastrointestinal panel.

Luminex this week said that the US Food and Drug Administration has cleared its xTAG Gastrointestinal Pathogen Panel for marketing in the US.

The clearance follows comments made last week at the JP Morgan Healthcare conference in San Francisco by CEO Patrick Balthrop, who told investors that the company expected clearance within a month.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.